Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

• Published in: Multiple sclerosis Vol. 27; no. 5; p. 790
• Main Authors: Mancinelli, Chiara Rosa, Scarpazza, Cristina, Cordioli, Cinzia, De Rossi, Nicola, Rasia, Sarah, Turrini, Maria Vittoria, Capra, Ruggero
• Format: Journal Article
• Language: English
• Published: England 01.04.2021
• Subjects: switching; extend interval dosing (EID); ocrelizumab; Natalizumab

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Forty-two RRMS patients, who switched from an extended interval dose (EID) of natalizumab to ocrelizumab,...